Kronos Bio To Present Data At ACR Convergence 2024 To Support P300 KAT Inhibition As An Approach To Anti-Inflammatory Therapy
Guggenheim Initiates Keros Therapeutics at Buy With $96 Price Target
Guggenheim Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $96
Guggenheim analyst Vamil Divan initiates coverage on $Keros Therapeutics(KROS.US)$ with a buy rating, and sets the target price at $96.According to TipRanks data, the analyst has a success rate of 53.
B of A Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $76
Keros Therapeutics Analyst Ratings
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $76
BofA Securities analyst Jason Zemansky maintains $Keros Therapeutics(KROS.US)$ with a buy rating, and adjusts the target price from $81 to $76.According to TipRanks data, the analyst has a success
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)
Keros Therapeutics Up Over 12%, on Pace for Largest Percent Increase Since January -- Data Talk
Keros Therapeutics Shares Are Trading Higher After the Company Announced It Closed Screening for Its Phase 2 Clinical TROPOS Trial.
Express News | Keros Therapeutics Inc - to Present Topline Data in Q2 2025
Express News | Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics(KROS.US) Director Sells US$11 Million in Common Stock
$Keros Therapeutics(KROS.US)$ Director ORBIMED ADVISORS LLC sold 250K shares of common stock on Aug 13, 2024 at an average price of $44.01 for a total value of $11 million. This transaction involves
Keros Therapeutics Insider Sold Shares Worth $11,002,500, According to a Recent SEC Filing
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Keros Therapeutics(KROS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.7% and a total average return
Form 144 | Keros Therapeutics(KROS.US) Insider Proposes to Sell 9.89 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 13, $Keros Therapeutics(KROS.US)$ Insider OrbiMed Private Investments VII, LP intends to sell 220.6K shares of its common stock on Aug 13, with a total market value of
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $102
Oppenheimer analyst Andreas Argyrides maintains $Keros Therapeutics(KROS.US)$ with a buy rating, and maintains the target price at $102.According to TipRanks data, the analyst has a success rate of 44
Oppenheimer Sticks to Its Buy Rating for Keros Therapeutics (KROS)
Strong Financials and Promising Clinical Trials Bolster Buy Rating for Keros Therapeutics
Buy Rating Affirmed for Keros Therapeutics as KER-065 Shows Promise in Obesity and Neuromuscular Disorders